Polyethylene glycol esters of polyunsaturated fatty acids

Details Polyethylene glycol esters of polyunsaturated fatty acids Polyethylene glycol esters of polyunsaturated fatty acids

1998-11-12

2003-08-26

Medley, Margaret (Department: 1714)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C523S105000

Reexamination Certificate

active

06610740

ABSTRACT:

The invention relates to polyethylene glycol esters of polyunsaturated fatty acids.
In many contexts polyunsaturated fatty acids are desirably made up as aqueous formulations that will be well tolerated in the body and will allow such acids to be well utilised especially in parental and topical applications. We have found that the use of polyethylene glycol esters of the fatty acids satisfies such requirements.
The invention thus provides, as nutritional, cosmetic or pharmaceutical formulations, polyethylene glycol esters in which the polyethylene glycol chain is terminated at one end by a polyunsaturated fatty acyl group preferably C
18
-C
22
and at the other end by a straight or branched chain C
1
-C
4
alkyl group, preferably a methyl group.
Such esters are desirably of formula.
A—(OCH
2
CH
2
)
n
—O—A
1
  (1)
where A is the polyunsaturated fatty acyl group; A
1
is a straight or branched chain alkyl group as above; and n is an integer to give a molecular weight of 1,000D to 6,000D.
A variety of nutritionally or otherwise bioactive C
18
-C
22
fatty acids with 2 to 6 unsaturations are known but the polyunsaturated fatty acids forming the present esters are preferably selected from the n-6 and n-3 essential fatty acids and most preferably the “delta 6-desaturated” acids that is to say the 18:3 n-6 and 18:4 n-3 and higher acids in the n-6 and n-3 series, particularly GLA, DGLA, AA, SA EPA and DHA. Their nomenclature and their conversions within biological systems are set out in table 1.
TABLE 1
n-6 EFA's
n-3 EFA's
18:2n-6
18:n-3
(Linoleic acid LA)
(&agr;-Linolenic acid, ALA)
↓
delta-6-desaturase
↓
18:3n-6
18:4n-3
(&ggr;-Linoienic acid GLA)
(Stearidonic acid)
↓
elongation
↓
20:3n-6
20:4n-3
(Dihomo-&ggr;-linoienic acid, DGLA)
↓
↓
delta-5-desaturase
20:4n-6
20:5n-3
(Arachidonic acid, AA)
(Eicosapentaenoic acid, EPA)
↓
elongation
↓
22:4n-6
22:5n-3
(Adrenic acid, AdrA
↓
delta-4-desaturase
↓
22:5n-6
22:6n-3
(Docosahexaenoic acid, DHA)
The acids, which in nature are of the all—cis configuration, are systematically named as derivatives of the corresponding octadecanoic, eicosanoic or docosanoic acids, e.g. z,z-octadeca-9,12-dienoic acid or z,z,z,z,z,z-docosa-4,7,10,13,16,19-hexaenoic acid, but numerical designations based on the number of carbon atoms, the number of centres of unsaturation and the number of carbon atoms from the end of the chain to where the unsaturation begins, such as, correspondingly, 18:2 n-6 or 22:6 n-3, are convenient. Initials, e.g. EPA, and shortened forms of the name e.g. eicosapentaenoic acid, are used as trivial names in some instances.
The preferred polyethylene glycol esters are as stated derived from the above twelve n-6 and n-3 essential fatty acids, desirably in all—cis form, but are not limited to them nor to acids in which the chain contains repeating —CH═CH—CH
2
— units. Columbinic acid (CA) and &agr;-parinaric acids (&agr;PA) are other suitable acids and their formulae are. respectively e,z,z-octadeca-5,9,12-trienoic acid and z,e,e,z-octadeca-9,11,13,15-tetraenoic acid. A further suitable acid is &agr;-eleostearic acid.
Compounds of type (1) may be synthesized by the reaction of terminally blocked polyethers of type RH, wherein R is a straight or branched chain C
1
-C
4
alkyl terminated polyethylene glycol chain as referred to earlier i.e. —(OCH
2
CH
2
)
n
—O—A
1
, with derivatives of fatty acids e.g. of type A—O—A or A—X where X is Cl or Br. The reaction may for example be carried out in a suitable solvent such as toluene or acetone at temperatures between 0° C. and 150° C. with or without a suitable base e.g. anhydrous potassium carbonate.
Compounds of type (1) may also be synthesized by the reaction of the polyethers, RH with fatty acids of type A—OH. The reaction may for example be carried out with or without a suitable solvent such as toluene or xylene in the presence of a suitable acid e.g. p-toluenesulphonic acid at temperatures between 50° C. and 180° C. so that the water formed is removed from the reaction e.g. by azeotropy or under vacuum.
Alternatively, the reaction may for example be carried out in a suitable solvent such as dichloromethane in the presence of a condensing agent e.g. dicyclohexylcarbodiimide and in the presence of a strong non-nucleophilic base e.g. 4-dimethylaminopyridine at temperatures between 0° C. and 50° C.
Compounds of type (1) may further for example be synthesized by the reaction of polyethers, RH with fatty acids of type A—OH or fatty acid esters of type A—O—Y, wherein Y is defined as an alkyl group containing a 1-4 carbon atoms which may be branched, unbranched, saturated or unsaturated e.g. vinyl, in the presence of a hydrolase enzyme with or without a suitable solvent e.g. toluene at temperatures between 20° C. and 80° C. such that the water or alcohol formed is removed from the reaction e.g. by molecular sieves or by vacuum.
Compounds of type (1) may still further be synthesized by the reaction of the polyethers. RH with fatty acid esters of type A—O—Y where Y is as above in the presence of a catalytic amount of an alcoholate of type M
30
OY
31
where Y is as above and M is an alkali or alkaline earth metal e.g. sodium. The reaction is carried out with or without a suitable solvent eg. toluene at temperatures between 50° C. and 180° C. such that the lower alcohol, HO—Y formed is removed from the reaction mixture e.g. by azeotropy or by vacuum.
The compounds of type (1) are typically from 0.5-30% particularly 5-30% and more particularly 5-20% soluble in water at 25° C. and by analysis are shown to contain from 60-100% of the theoretical amount of fatty acyl groups. The solubility in water confers major formulation advantages on the fatty acids allowing them to be used for oral, parenteral, enteral or topical administration as solutions, emulsions, mixtures, creams, lotions or other delivery systems known to those skilled in the art.


REFERENCES:
patent: 3871837 (1975-03-01), Bedague et al.
patent: 4032304 (1977-06-01), Dorer, Jr. et al.
patent: 4248726 (1981-02-01), Uchinuma et al.
patent: 4364743 (1982-12-01), Erner
patent: 4377667 (1983-03-01), Sakurai et al.
patent: 4816483 (1989-03-01), Georgieva et al.
patent: 5227403 (1993-07-01), Seto et al.
patent: 5308634 (1994-05-01), Cooper
patent: 5376398 (1994-12-01), Cooper et al.
patent: 5670540 (1997-09-01), Horrobin et al.
patent: 31 23 065 (1982-03-01), None
patent: 0 031 310 (1981-01-01), None
patent: 1338385 (1973-11-01), None
Patent Abstracts of Japan, vol. 013, No. 238 (C-603), Jun. 5, 1989 & JP 01 047701 A (ASAHI Denka Kogyo KK), Feb. 22, 1989, see abstract.
Patent Abstracts of Japan, vol. 012, No. 186 (C-500), May 31, 1988 & JP 62 290740 A (Miyoshi Oil & Fat Co Ltd), Dec. 17, 1987, see abstract.

Affiliated with

Also associated with

Rating

Polyethylene glycol esters of polyunsaturated fatty acids does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Polyethylene glycol esters of polyunsaturated fatty acids, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polyethylene glycol esters of polyunsaturated fatty acids will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3083019